A daily pill that mimics the body's own appetite-regulating hormone has shown meaningful results in late-stage trials, offering people with Type 2 diabetes a path toward weight loss and blood sugar control without ever picking up a needle. Eli Lilly's orforglipron sits at the intersection of medical progress and human preference — not the most powerful tool in the arsenal, but perhaps the most approachable one. As FDA approval approaches in 2026, the question shifts from whether the pill works to whether it will reach the people who need it most.
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
This is a pill. I think this still is going to have a significant role.
Mark
Why does the form of the drug matter so much? Isn't 10% weight loss still 10% weight loss?
Mimi
It matters because adherence matters. Some people have genuine needle phobia. Others simply prefer the routine of a daily pill to a weekly injection. If the form keeps someone in treatment longer, or gets someone into treatment who wouldn't otherwise try it, that's a real difference in outcomes.
Mark
But it's less effective. Doesn't that concern you?
Mimi
It does and it doesn't. Yes, the injectable versions produce more weight loss. But this pill still moved three-quarters of diabetic patients into non-diabetic blood sugar ranges. That's not a consolation prize—that's meaningful disease reversal for a lot of people.
Mark
What about the side effects? Ten percent of people quit because of nausea and digestive issues.
Mimi
That's the same rate you see with the injectables, actually. The side effect profile is comparable. The real question is whether people tolerate them better or worse when they're taking a pill daily versus injecting once a week. We don't know that yet.
Mark
So what's the catch? Why isn't everyone just switching to this?
Mimi
Partly because it doesn't exist yet—FDA approval is still expected in 2026. But also because some people will want the maximum weight loss the injectables provide. And honestly, we don't know what the price will be. Eli Lilly has no competition in this category right now, which could work either way.
Mark
Do you think this changes the obesity treatment landscape?
Mimi
I think it expands it. It's another tool. For some patients, it'll be the right choice. For others, the injectable will still be better. The real win is that more people now have options.
O Pulso
- A needle-free GLP-1 pill achieving 10.5% body weight loss and restoring non-diabetic blood sugar levels in three-quarters of participants has upended assumptions about what oral medications can accomplish.
- The gap between the pill's results and those of injectable rivals like Zepbound — which delivers nearly 15% weight loss in diabetic patients — creates a tension between accessibility and maximum effectiveness.
- Side effects including nausea and vomiting caused roughly 10% of high-dose participants to abandon treatment, a dropout rate double that of placebo takers and a reminder that convenience does not erase biological friction.
- Eli Lilly has already begun manufacturing stockpiles ahead of approval, a deliberate move to avoid the supply crises that left injectable GLP-1 patients stranded in recent years.
- With no oral competitor yet completing phase 3 trials, pricing remains the largest unresolved variable — and the one most likely to determine whether this breakthrough reaches everyday patients or remains out of reach.
A daily pill that mimics the body's own appetite-regulating hormone has shown meaningful results in late-stage trials, offering people with Type 2 diabetes a path toward weight loss and blood sugar control without ever picking up a needle. Eli Lilly's orforglipron sits at the intersection of medical progress and human preference — not the most powerful tool in the arsenal, but perhaps the most approachable one. As FDA approval approaches in 2026, the question shifts from whether the pill works to whether it will reach the people who need it most.
On Tuesday, Eli Lilly announced that orforglipron — an oral GLP-1 drug taken as a daily pill — produced significant results in late-stage trials for people with Type 2 diabetes and obesity. Adults on the highest dose lost an average of 23 pounds over 72 weeks, roughly 10.5% of their body weight, compared to just 5 pounds for those on placebo. FDA approval is expected by 2026.
The drug works by mimicking GLP-1, a hormone the body releases after eating to suppress appetite and regulate insulin. Unlike Mounjaro or Ozempic, orforglipron requires no injections and carries no food or water restrictions — a distinction that matters enormously to patients who fear needles or struggle with weekly shot routines. Three-quarters of participants on the highest dose reached an A1C of 6.5% or below, the threshold at which diabetes would no longer be diagnosed, starting from an average of 8.1%. Improvements in cholesterol, triglycerides, and blood pressure were also recorded.
The pill does carry trade-offs. Its weight loss falls short of injectable alternatives — Eli Lilly's own Zepbound delivers nearly 15% weight loss in diabetic patients. Side effects mirrored those of injectables: nausea, constipation, diarrhea, and vomiting. About 10% of high-dose participants stopped treatment due to these effects, twice the placebo dropout rate.
Physicians offered measured enthusiasm. Dr. Natalie Azar emphasized that the pill's form alone gives it an important role, while Dr. Melanie Jay cautioned that no version of these drugs eliminates the need for careful medical oversight. 'We still have so much to learn about how to use these medicines,' she said.
Eli Lilly has begun stockpiling pills ahead of approval to avoid the supply shortages that disrupted injectable rollouts. What remains unknown is pricing — as the first oral GLP-1 through phase 3 trials, orforglipron faces no direct competition, a position that could cut either way for patients hoping a pill might finally be within reach.
Eli Lilly announced Tuesday that an oral version of a GLP-1 drug called orforglipron has delivered measurable results in late-stage trials, offering people with Type 2 diabetes and obesity a needle-free alternative to the weekly injections that have dominated the weight-loss medication landscape. Adults taking the highest dose of the pill for 72 weeks lost an average of 23 pounds—about 10.5% of their body weight—compared to just 5 pounds for those on placebo. The company expects FDA approval by 2026.
The drug works by mimicking GLP-1, a hormone the body naturally produces after eating that suppresses appetite and helps regulate insulin. What sets orforglipron apart from existing treatments like Mounjaro and Ozempic is its form: a daily pill with no food or water restrictions, rather than a once-weekly injection. For people who fear needles or simply prefer swallowing a tablet, this represents a meaningful shift in how they might manage their condition.
The blood sugar control was particularly striking. Three-quarters of study participants who took the highest dose achieved an A1C level of 6.5% or less—the threshold at which a doctor would no longer classify someone as diabetic—starting from an average of 8.1%. Participants also saw improvements in LDL cholesterol, triglycerides, and systolic blood pressure. Dr. Dan Skovronsky, Eli Lilly's chief scientific officer, told NBC that these results mean some patients would no longer show signs of diabetes on standard testing.
But the pill does come with trade-offs. The weight loss it produces—10.5% in diabetic patients—falls short of what injectable GLP-1 drugs achieve. Zepbound, Eli Lilly's injectable version, delivers 21% weight loss in non-diabetic adults and nearly 15% in those with diabetes. Dr. Natalie Azar, a medical contributor to TODAY, acknowledged this gap while emphasizing that the pill still represents an important tool. "The big message here is that this is a pill," she said. "I think this still is going to have a significant role."
Side effects mirrored those of injectable GLP-1 drugs: nausea, constipation, diarrhea, and vomiting. About 10% of participants taking the highest dose stopped treatment because of these effects, double the rate among placebo takers. No liver damage was observed. The company has already begun manufacturing and stockpiling pills ahead of potential approval, a move designed to prevent the supply shortages that plagued injectable versions.
Dr. Shauna Levy, an obesity medicine physician at Tulane's Bariatric and Weight Loss Center, noted that the oral option expands treatment possibilities for patients who resist injections. Yet Dr. Melanie Jay, an obesity researcher at NYU Langone, offered a cautionary note: these drugs are not cure-alls and require careful medical oversight regardless of their form. "It is not a silver bullet, and we are finding that in real world practice, we still have so much to learn about how to use these medicines," she said.
One significant unknown remains pricing. As the first oral GLP-1 to complete phase 3 trials, orforglipron currently faces no competition in its category—a fact that could influence its cost relative to existing injectables. Whether the pill's simpler manufacturing process will translate to lower prices for patients remains unclear. What is certain is that demand for a needle-free GLP-1 option is likely to be substantial, even if it delivers somewhat less dramatic weight loss than the shots.
Citações Notáveis
The big message here is that this is a pill. I think this still is going to have a significant role.— Dr. Natalie Azar, medical contributor to TODAY
It is not a silver bullet, and we are finding that in real world practice, we still have so much to learn about how to use these medicines.— Dr. Melanie Jay, obesity researcher at NYU Langone
Quer a matéria completa?
Leia o original em TODAY ↗
Health & Medicine